Emergent BioSolutions to acquire US vaccines company

9 August 2018

Today PaxVax announced it has entered into a definitive agreement to be acquired by US biotech firm Emergent BioSolutions (NYSE: EBS).

Emergent will acquire PaxVax’ portfolio of commercialized vaccines (Vaxchora and Vivotif for cholera and typhoid, respectively) and pipeline for diseases including adenovirus and chikungunya.

The all cash transaction, valued at $270 million, will create the world’s largest independent specialty vaccine company with global R&D, manufacturing and commercial operations - and will empower the public with better protection against a number of emerging health threats. .

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK